3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Immunoglobulin Light-chain Amyloidosis
2
Paraproteinemias
1
Amyloidosis
1
Alzheimer Disease
1
Interventions
Dexamethasone
12
Melphalan
7
Calcium Dobesilate
6
Lenalidomide
5
Bortezomib
5
Cyclophosphamide
4
miridesap
3
ixazomib
2
Doxycycline
2
Biopsy
2
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
2
pomalidomide
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
daratumumab
1
carfilzomib
1
birtamimab
1
auricularum
1
Vinorelbine
1
Thalidomide
1
Tacrolimus
1
Pharmaceutical Preparations
1
Interleukin-2
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Gemcitabine
1
Filgrastim
1
Etanercept
1
Drug Evaluation
1
Blood Specimen Collection
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Amyloidosis
×
birtamimab
×
Clear all
NCT02632786
2019-04-05
PRONTO
Prothena Biosciences Ltd.
Phase 2
Completed
129 enrolled
18 charts